Comment from Viatris Inc.

Summary: Viatris Inc. supports the FDA's efforts to update the SUPAC guidances, emphasizing the need to retain core risk-based principles while modernizing the framework. They argue for the removal of prescriptive elements, the inclusion of modern science-based tools (like QbD and PACMPs), and better harmonization with ICH guidelines to reduce regulatory burden and improve efficiency.